ANI Pharma

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ANI Pharma posts record revenues, eyes growth in Rare Disease

ANI Pharmaceuticals delivered robust financial results, showcasing strong revenue growth and EBITDA improvement. The company's focus on Rare Disease and Generics businesses, along with strategic initiatives for 2023, positions it well for continued growth. Challenges in cash flow management and cautious information sharing require attention.

ANI Pharma reports record Q1 revenues, eyes Rare Disease M&A

ANI Pharma (ANIP) delivered strong financial performance in Q1 2023, with record revenues and raised full-year guidance, driven by successful product launches and operational efficiency.
The company's focus on sustainable growth, patient care, and strategic investments in the Rare Disease space position ANI for future success.
While facing challenges such as increased operating expenses and debt obligations, ANI's strengths in revenue growth and market reception of key products provide opportunities for continued expansion.
ANI's commitment to organic deleveraging, cash generation, and potential M&A activities underscore a strategic approach to long-term growth and financial stability.

ANI Pharma reports stellar Q2 results, eyes rare disease expansion

ANI Pharma delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and record EBITDA.
The company's focus on rare diseases and generics, along with a solid financial position, positions it well for future growth.
ANI Pharma faces challenges in maintaining growth momentum and navigating industry competition but has opportunities for expansion.

ANI Pharma reports record Q3 revenues, raises full-year guidance

ANI Pharmaceuticals (ANIP) delivered impressive Q3 results with record revenues and substantial growth in key segments. Despite market challenges, the company's strategic investments and raised guidance signal confidence in future performance and expansion.

ANI Pharmaceuticals reports record 2023 earnings, eyes growth opportunities

ANI Pharmaceuticals delivered a stellar performance in Q4 2023, achieving record revenue and profitability figures, driven by strong sales in key product segments.
While the company faces challenges in maintaining growth rates and navigating market dynamics, ANI Pharmaceuticals is well-positioned to capitalize on opportunities for expansion and innovation.
With a solid financial foundation, diverse product portfolio, and strategic growth outlook for 2024, ANI Pharmaceuticals remains poised for continued success and market leadership in the pharmaceutical industry.

ANI Pharma reports strong Q1 earnings, eyes Rare Disease growth

ANI Pharma's Q1 2024 performance reflects robust revenue growth across key segments, supported by strategic initiatives and a focus on innovation.
While facing challenges in R&D spending variability and supply tailwinds, the company remains well-positioned to capitalize on growth opportunities.
Opportunities lie in expanding the Rare Disease business, exploring new specialties for Cortrophin Gel, and pursuing strategic M&A for sustained growth.
ANI Pharma's prudent approach to capital deployment and confidence in growth through acquisitions underscore a promising outlook for future expansion.

ANI Pharma reports record revenues, announces Alimera acquisition for growth

ANI Pharma delivered a strong Q2 2024 performance with record revenues and significant growth in key product segments.
The proposed acquisition of Alimera Sciences signals ANI's strategic expansion into high-growth commercial products, enhancing its market position.
While facing integration challenges, ANI's raised guidance and focus on accretive EPS from the acquisition highlight a positive outlook for future growth.

ANI Pharmaceuticals (ANIP) reports record Q3 revenues and eyes rare disease growth in 2025

ANI Pharmaceuticals (ANIP) delivered a robust Q3 performance with record revenues and raised full-year guidance, driven by strong growth in Cortrophin Gel and generics business. The company's emphasis on rare diseases and new offerings positions it for continued growth in 2025. While challenges exist in the payer landscape and acquisition integration, ANIP's strategic focus on key specialties offers promising opportunities for expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes ANI (ANIP) a New Buy Stock

ANI Pharmaceuticals Inc. (ANIP) CEO Arthur Przybyl on Q1 2019 Results - Earnings Call Transcript

ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

ACI Worldwide

Bed Bath & Beyond

DXP Enterprises

Foot Locker

The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.

American Economy Hits the Gas: 5 Top Gainers

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

Is  (ANIP) Outperforming Other Medical Stocks This Year?

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

Coherus BioSciences

Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Coherus (CHRS) Catches Eye: Stock Jumps 6.9%

Palatin Technologies

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher

ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About ANI (ANIP) Rating Upgrade to Strong Buy

News for ANI Pharma Stock (ANIP)